Investors
News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 26, 2021CoVIC's animal efficacy data shows that Aridis' AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to date
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced...
-
Jul 19, 2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage...
-
Jul 12, 2021Texas Biomedical Research Institute and Aridis' data confirmed AR-712 binds to and neutralizes the Delta variant of SARS-CoV-2 virus
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced...
-
May 11, 2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...
-
Mar 30, 2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...